Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
- Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.
- Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
- Associated Conditions
- Oral Mucositis
- Associated Therapies
- -
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 47
- Registration Number
- NCT00109031
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 188
- Registration Number
- NCT00101582
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-10-27
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 100
- Registration Number
- NCT00094861
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath